Neurology Specific Literature Search   
 
[home][thesaurus]
    

Differential
(Click to cross reference)
advances in neurology
adverse drug reaction
algorithm
andexanet
antiarrhythmic drugs
anticoagulant, complications of
anticoagulant, contraindications
anticoagulant, discontinuation
anticoagulant, restarting
anticoagulant, reversal of
anticoagulant, treatment
anticoagulant, treatment in CVD
anticoagulation effect
anticoagulation, perioperative
apixaban
argatroban
arrhythmia, cardiac
aspirin
asymptomatic
atrial appendage closure
atrial fibrillation
atrial fibrillation, nonvalvular
atrial fibrillation, risk stratification
atrial fibrillation, surgical treatment
atrial fibrillation, treatment
atrial flutter
atrial septal defect
bedridden
breast feeding
bridge therapy
bronchoscopy
cancer associated hypercoagulation
cancer, cerebrovascular accident complicating patients with
carcinoma
cardiomyopathy
carotid artery occlusion, intracranial
carotid artery occlusion, perioperative
CAT scan, abnormal
cataract surgery
cerebral embolism
cerebral embolism, cardiac origin
cerebral embolism, mechanical extraction
cerebral infarction
cerebral venous thrombosis
cerebrovascular accident
cerebrovascular accident, acute management of
cerebrovascular accident, cardiac disease causing
cerebrovascular accident, complications with
cerebrovascular accident, cryptogenic
cerebrovascular accident, postoperative
cerebrovascular accident, prevention of
cerebrovascular accident, primary prevention
cerebrovascular accident, recurrent
cerebrovascular accident, secondary prevention
cerebrovascular accident, severity
cerebrovascular accident, thrombolytic agents in treatment
cerebrovascular accident, women
cerebrovascular accident, young adult
CHADS-VaSC score
ciraparantag
clopidogrel
clot retrieval
colonoscopy
compliance
complications
controversies in neurology
cost
cost effectiveness
coumarin
coumarin, restarting treatment
coumarin, stopping treatment
cryoablation
dabigatran
dabigatran, dose
deafness, unilateral
delivery, complicated
dental procedure, neurologic complications with
dialysis
drug interactions
dural sinus thrombosis
dyspepsia
edoxaban
efficacy
electromyogram
embolic stroke of unknown source
embolism, systemic
endoscopic surgery
endoscopy
endovascular therapy
enoxaparin
evidence-based research
factor Xa inhibitor
falling
fibrinolytic agents
fibrinolytic agents, complications
fibrinolytic agents, contraindications
fibrinolytic agents, intra-arterial local infusion
fibrinolytic therapy, selection criteria
gastrointestinal bleeding
HAS-BLED score
head injury
headache
heart valve, prosthetic
hemorrhagic diathesis
hemostatic therapy
heparin
heparin, low-molecular-weight
heparinoid, low molecular weight
hepatic failure
hip arthroplasty
Holter monitoring
hormone replacement
hormone therapy
iatrogenic neurologic disorders
idarucizumab
incidental finding
INR value, time in range
INR values
intracerebral hemorrhage
intracerebral hemorrhage, progression of
intracerebral hemorrhage, silent
intracerebral hemorrhage, treatment of
intracerebral hemorrhage, volume
intracranial hemorrhage
labor, complicated
left atrial appendage, percutaneous closure
left ventricular dysfunction
liver disease
liver function enzymes
menopause
MERCI trial
microhemorrhage, intracerebral
middle cerebral artery, occlusion of
mimics
misdiagnosis
mortality
MRI, abnormal
myocardial infarction
neurologic complications of, surgery
neuroradiology, interventional
NIH stroke scale
non-vitamin K antagonist oral anticoagulants
non-vitamin K antagonist oral anticoagulants, coagulation test
number needed to treat
old age, neurology of
oral contraceptives
oral contraceptives, cerbrovascular disease and
ovarian induction
pacemaker, cardiac-transvenous
partial thromboplastin time
patent foramen ovale, surgical treatment of
patient information and support
peri-procedural
platelet inhibiting drugs
platelet inhibiting drugs, combined
platelet inhibiting drugs, discontinuation
postoperative neurologic complications
practice guidelines
pregnancy, neurologic complications in
prevention of neurologic disorders
prognosis
prothrombin complex concentrate
prothrombin time
prothrombin time, prolonged
radiofrequency ablation
rapid thromboelasticity
recanalization, arterial
recurrent
RELY trial
renal failure
reperfusion
RESPECT trial
review article
risk factors
risk factors, modification
risk stratification
risk-benefit assessment
rivaroxaban
ROCKET - AF trial
safety
serum alanine aminotransferase
solitaire device
SPORTIF trial
stent, carotid artery
subarachnoid hemorrhage
subarachnoid hemorrhage, cerebral convexity
subdural hematoma
T lesion of MCA-ICA
teratogenesis
teratogenic drugs
thrombectomy
thrombin inhibitor
thrombolysis, mechanical
thrombophlebitis
thrombus, mural
tissue plasminogen activator, intravenous
transient ischemic attack
transient neurologic deficit
transluminal angioplasty, coronary artery
transurethral prostatectomy
trauma
treatment of neurologic disorder
venous thrombosis, non-cerebral
vitamin K
vitamin K antagonist
Watchman device
ximelagatran
Showing articles 450 to 500 of 865 << Previous Next >>

High-Dose Atorvastatin After Stroke or Transient Ischemic Attack
NEJM 355:549-559,613, The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators, 2006

Discontinuation of Statin Treatment in Stroke Patients
Stroke 37:2640-2643, Endres,M. &Laufs,U., 2006

Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimers Disease
NEJM 355:1525-1538,1604, Schneider,L.S.,et al, 2006

Effect of Donepezil on Motor and Cognitive Function in Huntington Disease
Neurol 67:1268-1271, Cubo,E.,et al, 2006

Infusion-Related Hypersensitivity Reactions During Natalizumab Treatment
Neurol 67:1717-1718, Phillips,J.T.,et al, 2006

Coxibs and Alzheimers Disease: Should They Stay or Should They Go?
Ann Neurol 59:219-228, Firuzi,O. &Pratico,D., 2006

Chronic Daily Headache
NEJM 354:158-165, Dodick,D.W., 2006

Natalizumab Plus Interferon Beta -1a for Relapsing Multiple Sclerosis
NEJM 354:911-923,965, Rudick,R.A.,et al, 2006

A Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
NEJM 354:899-910,965, Polman,C.H.,et al, 2006

Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy
NEJM 354:924-933,965, Yousry,T.A.,et al, 2006

Duloxetine-induced Syndrome of Inappropriate Antidiuretic Hormone Secretion and Seizures
Neurol 66:773-774, Maramatton,B.V., 2006

Clinicopath Conf, Diffuse Large B-Cell Lymphoma, EBV-Positive, with Immunosuppression
NEJM 354:1178-1184, Case 8-2006, 2006

Practice Parameter: Evaluation and Treatment of Depression, Psychosis, and Dementia in Parkinson Disease (An Evidence-Based Review)
Neurol 66:996-1002, Miyasaki,J.M.,et al, 2006

Donepezil in Patients with Severe Alzheimers Disease: Double-Blind, Parallel-Group, Placebo-Controlled Study
Lancet 367:1057-1065,1031, Winblad,B.,et al, 2006

Statin-Associated Myasthenia Gravis
Medicine 85:82-85, Purvin,V.,et al, 2006

Vitamin E and Donepezil for the Treatment of Mild Cognitive Impairment
NEJM 352:2379-2388,2439, Petersen,R.C.,et al, 2005

Statin Use and the Risk of Incident Dementia
Arch Neurol 62:1047-1051, Rea,T.D.,et al, 2005

Lipid-Lowering Agent Use at Ischemic Stroke Onset is Associated with Decreased Mortality
Neurol 65:253-258, Elkind,M.S.V.,et al, 2005

Cholinesterase Inhibitors for Patients with Alzheimers Disease: Systematic Review of Randomised Clinical Trials
BMJ 331:321-323, Kaduszkiewicz,H.,et al, 2005

Diagnosis and Initial Management of Parkinsons Disease
NEJM 353:1021-1027, Nutt,J.G.&Wooten,G.F., 2005

Efficacy and Safety of Cholesterol-Lowering Treatment: Prospective Meta-Analysis of Data from 90056 Participants in 14 Randomised Trials of Statins
Lancet 366:1267-1278, Cholesterol Treatment Trialists (CTT) Collaborators, 2005

Infliximab and Reactivation of Cerebral Toxoplasmosis
NEJM 353:1530-1531, Callegari,P.E., 2005

Statins Are Associated With Better Outcomes After Carotid Endarterectomy in Symptomatic Patients
Stroke 36:2072-2076,2058, Kennedy,J.,et al, 2005

Statins and Cognitive Functioning the Elderly
Neurol 65:1388-1394, Bernick,C.,et al, 2005

Rhabdomyolysis: An Evaluation of 475 Hospitalized Patients
Medicine 84:377-385, Melli,G.,et al, 2005

Lipid Lowering Agents Are Associated With a Slower Cognitive Decline in Alzheimers Disease
JNNP 76:1624-1629, Masse,I.,et al, 2005

Efficacy of TNF a Blockade in Cyclophosphamide Resistant Neuro-Behet Disease
JNNP 76:1733-1735, Ribi,C.,et al, 2005

Two Patients With COMT Inhibitor-Induced Hepatic Dysfunction and UGT1A9 Genetic Polymorphism
Neurol 65:1820-1822, Martignoni,E.,et al, 2005

Terminating Migraine with Allodynia and Ongoing Central Sensitization Using Parenteral Administration of COX1/COX2 Inhibitors
Headache 45:850-861, Jakubowski,M.,et al, 2005

A Randomized Placebo-Controlled Trial of Rasagiline in Levodopa-Treated Patients with Parkinson Disease and Motor Fluctuations
Arch Neurol 62:241-248, The PRESTO Study, 2005

The Serotonin Syndrome
NEMJ 352:1112-20, Boyer, E.W. & Shannon, M., 2005

Rasagiline as an Adjunct to Levodopa in Patients With Parkinsons Disease and Motor Fluctuations (LARGO, Lasting Effect in Adjunct Therapy With Rasagiline Given Once Daily, Study)
Lancet 365:947-954, 914, Rascol,O., et al, 2005

Expanding Indications for Statins in Cerebral Ischemia
Arch Neurol 62:67-72,23, Ovbiagele,B.,et al, 2005

Metabolic Patterns Associated with the Clinical Response to Galantamine Therapy
Arch Neurol 62:721-728, Mega,M.S.,et al, 2005

Atorvastatin for the Treatment of Mild to Moderate Alzheimer Disease
Arch Neurol 62:753-757, Sparks,D.L.,et al, 2005

Nonarteritic Ischemic Optic Neuropathy Developing Soon After Use of Sildenafil (Viagra): A Report of Seven New Cases
J Neuroophthalmol 25:9-13, Pomeranz,H. &Bhavsar,A.R., 2005

Donepezil for Dementia in Parkinsons Disease: A Randomised, Double Blind, Placebo Controlled, Crossover Study
JNNP 76:934-939,903, Ravina,B.,et al, 2005

Effect of Pravastatin on Cerebral Infarcts and White Matter Lesions
Neurol 64:1807-1809, ten Dam,V.H.,et al, 2005

Short-Term Paroxetine Treatment Does Not Alter the Motor Response to Levodopa in PD
Neurol 64:1797-1798, Chung,K.A.,et al, 2005

HMG-CoA Reductase Inhibitors Improve Acute Ischemic Stroke Outcomes
Stroke 36:1298-1300, Moonis,M.,et al, 2005

Pharmacological treatment of Neuropsychiatric Symptoms of Dementia
JAMA 293:596-608, Sink,K.M.,et al, 2005

Underappreciated Statin-Induced Myopathic Weakness Causes Disability
Neurorehabil Neural Repair 19:259-263, Dobkin,B.H., 2005

Oral Simvastin Treatment in Relapsing-Remitting Multiple Sclerosis
Lancet 363:1607-1608,1570, Vollmer,T.,et al, 2004

Hypercholesterolemia, HMG-CoA Reductase Inhibitors, and Risk of Intracerebral Hemorrhage
Stroke 35:1360-1364, Woo,D.,et al, 2004

Statins in Stroke Prevention and Carotid Artherosclerosis, Systematic Review and Up-to-Date Meta-Analysis
Stroke 35:2902-2909, Amarenco,P.,et al, 2004

Incidence of Hospitalized Rhabdomyloysis in Patients Treated With Lipid-Lowering Drugs
JAMA 292:2585-2590, Graham,D.J.,et al, 2004

Statin-Associated Exacerbation of Myasthenia Gravis
Neurol 63:2188, Cartwright,M.S.,et al, 2004

Reduced Risk of Alzheimer Disease in Users of Antioxidant Vitamin Supplements
Arch Neurol 61:82-88, Zandi,P.P.,et al, 2004

Memantine Treatment in Patients with Moderate to Severe Alzheimer Disease Already Receiving Donepezil, A Randomized Controlled Trial
JAMA 291:317-324, Tariot,P.N.,et al, 2004

Effects of Cholesterol-lowering with Simvastatin on Stroke and Other Major Vascular Events in 20 536 People with Cerebrovascular Disease or Other High-Risk Conditions
Lancet 363:757-767, Heart Protection Study Collaborative Group, 2004



Showing articles 450 to 500 of 865 << Previous Next >>